Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Esnouf

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Acta Crystallographica. Section D, Biological Crystallography|May 1, 1995
A strategy for rapid and effective refinement applied to black swan lysozymeZ Rao, R Esnouf, N Isaacs, et al.
Biochemical and Biophysical Research Communications|October 26, 1999
Characterization of multiple nuclear localization signals in herpes simplex virus type 1 thymidine kinaseB Degrève, R Esnouf, E De Clercq, et al.
Molecular Pharmacology|February 13, 2001
Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinaseB Degrève, R Esnouf, E De Clercq, et al.
AIDS Research and Human Retroviruses|March 10, 1998
A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781J Balzarini, H Pelemans, R Esnouf, et al.
Molecular Pharmacology|April 25, 2000
Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitorsH Pelemans, R Esnouf, E De Clercq, et al.
Molecular Pharmacology|November 28, 2000
Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosineB Degrève, R Esnouf, E De Clercq, et al.
Nature Structural Biology|April 1, 1995
Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitorsR Esnouf, J Ren, C Ross, et al.
The Journal of General Virology|February 17, 2000
Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase geneG Andrei, R Snoeck, E De Clercq, et al.
Chemistry & Biology|September 12, 2000
Solution structure of a HNA-RNA hybridE Lescrinier, R Esnouf, J Schraml, et al.
Structure (London, England : 1993)|September 15, 1995
The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor designJ Ren, R Esnouf, A Hopkins, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Acta Crystallographica. Section D, Biological Crystallography|May 1, 1995
A strategy for rapid and effective refinement applied to black swan lysozymeZ Rao, R Esnouf, N Isaacs, et al.
Biochemical and Biophysical Research Communications|October 26, 1999
Characterization of multiple nuclear localization signals in herpes simplex virus type 1 thymidine kinaseB Degrève, R Esnouf, E De Clercq, et al.
Molecular Pharmacology|February 13, 2001
Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinaseB Degrève, R Esnouf, E De Clercq, et al.
AIDS Research and Human Retroviruses|March 10, 1998
A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781J Balzarini, H Pelemans, R Esnouf, et al.
Molecular Pharmacology|April 25, 2000
Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitorsH Pelemans, R Esnouf, E De Clercq, et al.
Molecular Pharmacology|November 28, 2000
Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosineB Degrève, R Esnouf, E De Clercq, et al.
Nature Structural Biology|April 1, 1995
Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitorsR Esnouf, J Ren, C Ross, et al.
The Journal of General Virology|February 17, 2000
Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase geneG Andrei, R Snoeck, E De Clercq, et al.
Chemistry & Biology|September 12, 2000
Solution structure of a HNA-RNA hybridE Lescrinier, R Esnouf, J Schraml, et al.
Structure (London, England : 1993)|September 15, 1995
The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor designJ Ren, R Esnouf, A Hopkins, et al.
Pageof 2